Prime Medicine (PRME) Return on Capital Employed (2022 - 2026)
Prime Medicine's (PRME) quarterly Return on Capital Employed came in at 73.15% in Q1 2026, up 99.0% YoY from 36.76% in Q1 2025, and down 14.61% on a QoQ basis from 63.83% in Q4 2025.
Prime Medicine (PRME) Return on Capital Employed (2022 - 2026) Analysis & Trends
Prime Medicine (PRME) has 5 years of Return on Capital Employed data on file, last reported at 73.15% in Q1 2026.
- Quarterly Return on Capital Employed rose 99.0% year-over-year to 73.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73.15% (up 99.0% YoY) and the FY2025 annual result came in at 73.71%, up 2376.0% from the prior year.
- Return on Capital Employed retreated to 73.15% in Q1 2026, from 63.83% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 43.42% in Q1 2023 to a low of 127.94% in Q4 2023.
- A 5-year average of 74.79% and a median of 73.65% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 8330 bps — and 2024, when it jumped 5489 bps.
- Tracing PRME's Return on Capital Employed over 5 years: stood at 44.64% in 2022, then tumbled by 187 bps to 127.94% in 2023, then jumped by 43 bps to 73.04% in 2024, then rose by 13 bps to 63.83% in 2025, then dropped by 15 bps to 73.15% in 2026.
- The last three Return on Capital Employed figures came in at 73.15% (Q1 2026), 63.83% (Q4 2025), and 68.68% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | -81.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -81.82% |
| Mar 31, 2026 | -73.15% |
| Dec 31, 2025 | -63.83% |
| Sep 30, 2025 | -68.68% |
| Jun 30, 2025 | -75.78% |
| Mar 31, 2025 | -74.14% |
| Dec 31, 2024 | -73.04% |
| Sep 30, 2024 | -87.58% |
| Jun 30, 2024 | -84.41% |
| Mar 31, 2024 | -93.39% |
| Dec 31, 2023 | -127.94% |
| Sep 30, 2023 | -79.51% |
| Jun 30, 2023 | -57.60% |
| Mar 31, 2023 | -43.42% |
| Dec 31, 2022 | -44.64% |